Copyright
©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 7, 2016; 22(29): 6573-6581
Published online Aug 7, 2016. doi: 10.3748/wjg.v22.i29.6573
Published online Aug 7, 2016. doi: 10.3748/wjg.v22.i29.6573
Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistance
Miguel Jiménez-Pérez, UGC de Aparato Digestivo, Unidad de Hepatología-Trasplante Hepático, Hospital Universitario Regional de Málaga, 29010 Malaga, Spain
Miguel Jiménez-Pérez, Rocío González-Grande, Pilar España Contreras, Isabel Pinazo Martínez, Jesús de la Cruz Lombardo, Raúl Olmedo Martín, Liver transplantation and hepatology unit, UGC de Aparato Digestivo Hospital Regional Universitario, 29010 Malaga, Spain
Author contributions: Jiménez-Pérez M, González-Grande R, España Contreras P, Pinazo Martínez I, de la Cruz Lombardo J and Olmedo Martín R contributed equally to this work.
Conflict-of-interest statement: The authors have no conflict of interest to report.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Miguel Jiménez-Pérez, MD, UGC de Aparato Digestivo, Unidad de Hepatología-Trasplante Hepático, Hospital Universitario Regional de Málaga, Avenida Carlos Haya, 29010 Malaga, Spain. mjimenezp@commalaga.com
Telephone: +34-610-95935 Fax: +34-951-291941
Received: March 22, 2016
Peer-review started: March 22, 2016
First decision: May 12, 2016
Revised: May 25, 2016
Accepted: June 15, 2016
Article in press: June 15, 2016
Published online: August 7, 2016
Peer-review started: March 22, 2016
First decision: May 12, 2016
Revised: May 25, 2016
Accepted: June 15, 2016
Article in press: June 15, 2016
Published online: August 7, 2016
Core Tip
Core tip: The use of direct-acting antivirals (DAAs) to treat chronic hepatitis C has resulted in a significant increase in rates of sustained viral response as compared with the standard treatment of peginterferon/ribavirin. The presence of resistance-associated variants (RAVs) can reduce viral sensitivity to DAAs, thus limiting the efficacy of these drugs . As well as the presence of RAVs, virological failure is generally associated with other factors related with a poor response. Nonetheless, therapeutic failure can still occur in the absence of detectable RAVs and after the use of highly effective DAAs, so that the true clinical impact of the RAVs remains to be determined.